title: Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.
abstract: Lytic activation of Epstein-Barr virus (EBV) is central to its life cycle and to most EBV-related diseases. However, not every EBV-infected B cell is susceptible to lytic activation. This lack of uniform susceptibility to lytic activation also directly impacts the success of viral oncolytic therapy for EBV cancers, yet determinants of susceptibility to lytic induction signals are not well understood. To determine if host factors influence susceptibility to EBV lytic activation, we developed a technique to separate lytic from refractory cells and reported that EBV lytic activation occurs preferentially in cells with lower levels of signal transducer and activator of transcription 3 (STAT3). Using this tool to detect single cells, we now extend the correlation between STAT3 and lytic versus refractory states to EBV-infected circulating B cells in patients with primary EBV infection, leading us to investigate whether STAT3 controls susceptibility to EBV lytic activation. In loss-of-function and gain-of-function studies in EBV-positive B lymphoma and lymphoblastoid cells, we found that the levels of functional STAT3 regulate susceptibility to EBV lytic activation. This prompted us to identify a pool of candidate cellular genes that might be regulated by STAT3 to limit EBV lytic activation. From this pool, we confirmed increases in transcript levels in refractory cells of a set of genes known to participate in transcription repression. Taken together, our findings place STAT3 at a critical crossroads between EBV latency and lytic activation, processes fundamental to EBV lymphomagenesis.
authors: Division of Infectious Diseases, Department of Pediatrics and Stony Brook Children's Hospital, Stony Brook University, Stony Brook, New York, USA.
authors: Erik R
authors: ER
authors: Hill
authors: Siva
authors: S
authors: Koganti
authors: Jizu
authors: J
authors: Zhi
authors: Cynthia
authors: C
authors: Megyola
authors: Alexandra F
authors: AF
authors: Freeman
authors: Umaimainthan
authors: U
authors: Palendira
authors: Stuart G
authors: SG
authors: Tangye
authors: Paul J
authors: PJ
authors: Farrell
authors: Sumita
authors: S
authors: Bhaduri-McIntosh
mesh_terms: D000293:Adolescent; D001402:B-Lymphocytes / Q000276:immunology* / Q000821:virology*; D045744:Cell Line, Tumor; D002648:Child; D004854:Herpesvirus 4, Human / Q000276:immunology* / Q000502:physiology*; D054884:Host-Pathogen Interactions; D006801:Humans; D050796:STAT3 Transcription Factor; D014775:Virus Activation
chemical_list: D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human
references: Proc Natl Acad Sci U S A. 1983 May;80(9):2762-6
references: 6302703
references: Nature. 2007 Aug 30;448(7157):1058-62
references: 17676033
references: Cancer Res. 2002 Jul 1;62(13):3773-81
references: 12097288
references: Nat Protoc. 2009;4(1):44-57
references: 19131956
references: Genes Dev. 2002 Apr 15;16(8):919-32
references: 11959841
references: Nat Rev Immunol. 2007 Jan;7(1):41-51
references: 17186030
references: J Vis Exp. 2011 Nov 08;(57):
references: 22090023
references: Cancer Res. 2002 Mar 15;62(6):1920-6
references: 11912175
references: J Infect Dis. 2007 Feb 15;195(4):483-92
references: 17230407
references: Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5
references: 22190485
references: J Virol. 2005 Nov;79(22):14102-11
references: 16254345
references: Cancer Res. 2005 Feb 1;65(3):939-47
references: 15705894
references: PLoS Pathog. 2010 Aug 19;6(8):e1001054
references: 20808903
references: J Virol. 2003 Apr;77(8):5000-7
references: 12663807
references: Cancer Lett. 2007 Jun 28;251(2):199-210
references: 17129668
references: J Immunol. 2009 Jan 1;182(1):21-8
references: 19109129
references: Blood. 1997 Mar 1;89(5):1665-77
references: 9057649
references: J Virol. 2001 Mar;75(6):2929-37
references: 11222718
references: J Exp Med. 2002 Apr 1;195(7):893-905
references: 11927633
references: Blood. 2001 Aug 15;98(4):972-8
references: 11493441
references: J Virol. 2002 Jun;76(11):5612-26
references: 11991990
references: J Virol. 2003 Apr;77(7):4139-48
references: 12634372
references: J Virol. 2005 Nov;79(22):13993-4003
references: 16254335
references: N Engl J Med. 1989 Mar 16;320(11):689-95
references: 2537928
references: Nat Rev Cancer. 2002 Oct;2(10):740-9
references: 12360277
references: J Gen Virol. 2011 Aug;92(Pt 8):1760-1768
references: 21490247
references: Nat Med. 2008 Oct;14(10):1118-22
references: 18776891
references: Blood. 1991 Sep 1;78(5):1162-5
references: 1652308
references: J Virol. 2010 Jan;84(2):993-1004
references: 19889776
references: N Engl J Med. 2007 Oct 18;357(16):1608-19
references: 17881745
references: J Cancer Res Clin Oncol. 2009 Mar;135(3):329-37
references: 19009309
references: J Exp Med. 2010 Jan 18;207(1):155-71
references: 20048285
references: Chem Biol. 2006 Nov;13(11):1235-42
references: 17114005
references: Cancer Res. 2003 Aug 1;63(15):4472-80
references: 12907620
references: J Virol. 2004 May;78(10):5194-204
references: 15113901
references: J Clin Virol. 2011 Sep;52(1):33-7
references: 21684200
references: J Virol. 2008 May;82(10):4706-19
references: 18337569
references: PLoS Biol. 2011 Apr;9(4):e1001046
references: 21526222
references: Immunity. 2011 Nov 23;35(5):806-18
references: 22118528
references: J Exp Med. 2008 Jul 7;205(7):1551-7
references: 18591410
references: J Virol Methods. 2006 Oct;137(1):103-14
references: 16843536
references: Nature. 1996 Feb 15;379(6566):645-8
references: 8628398
references: Blood. 2007 Mar 15;109(6):2571-8
references: 17119113